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Aims Vascular calcification is a major cause of morbidity and mortality. Fibroblast growth factor-2 (FGF-2) plays an
instructive role in osteogenesis and bone development, but its role in vascular calcification was unknown.
Therefore, we investigated the involvement of FGF-2 in vascular calcification and determined the mechanism by
which it regulates this process.
....................................................................................................................................................................................................
Methods
and results
We demonstrate that FGF-2 expression is increased in vascular smooth muscle cells (VSMCs) induced to deposit a
mineralized matrix by incubation with b-glycerophosphate. FGF-2 is also localized to sites of calcification within
human atherosclerotic plaques. The expression of syndecan-4, a heparan sulfate proteoglycan which regulates FGF-
2 signalling, is also increased in mineralizing VSMCs and co-localizes with FGF-2 in human calcified atherosclerotic
plaques. Exogenous FGF-2 inhibits VSMC mineralization, and this inhibition is reduced when syndecan-4 expression
is knocked-down using siRNA. Biochemical inhibition of FGFR signalling using a pan FGFR inhibitor (BGJ398) or
knocking-down syndecan-4 expression in VSMCs using siRNA increases VSMC mineralization. These increases are
prevented by inhibiting transforming growth factor-b (TGFb) signalling with SB431542, suggesting cross-talk
between FGF-2 and TGFb signalling is crucial for the regulation of VSMC mineralization. Syndecan-4 can also regu-
late FGF-2 signalling directly via protein kinase Ca (PKCa) activation. Biochemical inhibition of PKCa activity using
Go¨6976, or siRNA-mediated suppression of PKCa expression increases VSMC mineralization; this increase is also
prevented with SB431542. Finally, the ability of FGF-2 to inhibit VSMC mineralization is reduced when PKCa
expression is knocked-down.
....................................................................................................................................................................................................
Conclusion This is the first demonstration that syndecan-4 promotes FGF-2 signalling, and in turn, suppresses VSMC mineraliza-
tion by down-regulating TGFb signalling. Our discoveries that FGF-2 and syndecan-4 expression is increased in min-
eralizing VSMCs and that PKCa regulates FGF-2 and TGFb signalling in VSMCs suggests that the syndecan-4/FGF-2/
TGFb signalling axis could represent a new therapeutic target for vascular calcification.
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1. Introduction
Vascular calcification is the formation of mineralized tissue, bone and/or
cartilage within the vessel wall. Most patients with cardiovascular disease
have some calcification, although it is most prevalent in patients with
chronic kidney disease, type 2 diabetes mellitus and atherosclerosis.1,2
Calcification is not only highly prevalent in these diseases, but there is
now substantial evidence that it contributes to the morbidity and mortal-
ity associated with these common conditions.3,4
Vascular calcification is an active cell-regulated process, involving the
osteogenic differentiation of vascular smooth muscle cells (VSMCs),
VSMC apoptosis, calcifying matrix vesicle/exosome release, and matrix
mineralization.5,6 Existing approaches for the prevention of vascular cal-
cification are limited; therefore, there is an urgent need to identify new
therapeutic targets to treat this devastating pathology.
The fibroblast growth factors (FGFs) are a large family of secreted gly-
coproteins that can be classified as either paracrine- or endocrine-acting.
Paracrine FGFs, such as FGF-2, are readily sequestered to the extracellu-
lar matrix by heparan sulfate proteoglycans (HSPGs) which limits their
diffusion within the extracellular space. For signal propagation, the para-
crine FGFs bind to a cell surface FGF-receptor (FGFR1-5) in a ternary
complex consisting of FGF, FGFR and HPSGs leading to the activation of
downstream signalling events via phospholipase Cc and protein kinase C
(PKC), Ras-Erk1/2 or PI3K-Akt.7
FGF-2 is a critical regulator of osteogenesis and bone development,8,9
although its role in this process is complex. Bone formation and minerali-
zation are reduced in FGF-2-null mice.10,11 However, whilst short-term
FGF-2 treatment stimulates matrix mineralization in calvarial osteo-
blasts12,13 and mesenchymal stem cells,14 continuous FGF-2 treatment
inhibits mineralization by these cells.12–16 These studies suggest that
FGF-2 is required to promote bone mineralization, but then must be
down-regulated so mineralization can proceed.
Previous studies have shown that short-term FGF-2 treatment stimu-
lates the expression of osteogenic markers in rat VSMCs.17 However,
the potential role of FGF-2 in VSMC mineralization is currently
unknown. Therefore, this study investigated whether FGF-2 regulates
VSMC mineralization. We demonstrate that FGF-2/FGFR signalling plays
an inhibitory role in this process by interacting with syndecan-4 and
down-regulating transforming growth factor-b (TGFb) signalling in
VSMCs.
2. Methods
Detailed experimental protocols are in the Supplementary material
online.
2.1 Reagents
Reagents were analytical grade and obtained from Sigma-Aldrich (UK)
unless otherwise stated. Recombinant human FGF-2 (#100-18B) was
from PeproTech (UK), recombinant human TGFb1 (#240-B) from R&D
Systems (UK), BGJ398 from Santa Cruz (USA), Go¨6976 from Cell
Signaling Technology (USA), and SB431542 from Sigma-Aldrich (UK). An
equivalent volume of vehicle was used a control for each compound in
experiments: 0.1% (w/v) bovine serum albumin (BSA) in 5 mM TRIS for
FGF-2, dimethyl sulfoxide (DMSO) for BGJ398, Go¨6976 and SB431542,
and 0.1% (w/v) BSA in 4 mM HCl for TGFb1. Antibodies to phosphory-
lated Smad2 (#3108), Smad2 (#5339), protein kinase Ca (PKCa, #2056),
phosphorylated Akt (#4060), Akt (#9272), phosphorylated Erk1/2
(#4377), and Erk1/2 (#4695) were from Cell Signaling Technology
(USA). Antibodies to syndecan-4 were from Santa Cruz (sc-12766) or
Biovision, USA (#3644). Antibodies to FGF-2 (sc-79) were from Santa
Cruz (USA), phosphorylated PKCa (07-790) from Merck Millipore
(Germany), and b-actin (#A1978) from Sigma-Aldrich (UK).
2.2 Immunohistochemistry
Human atherosclerotic coronary arteries were used for the detection of
FGF-2 (n= 7) and syndecan-4 (n= 5) by immunohistochemistry.18
Calcification was detected using von Kossa staining. Images were
acquired using a 20x/0.80 Plan Apo objective using the 3 D Histech
Pannoramic 250 Flash II slide scanner. Human tissue was obtained with
informed consent and with approval from the Local and National
Research Ethics Committees (STH 16346, 12/NW/0036). This study
conforms to the Declaration of Helsinki.
2.3 Cell culture
Bovine VSMCs were isolated from aortic explants obtained from a local
abattoir, and routinely cultured in high glucose Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 2 mM L-glutamine, 100 U/
mL penicillin, 1.4lM streptomycin, 1 mM sodium pyruvate, 1x non-
essential amino acids and 10% (v/v) fetal calf serum (FCS), referred to as
10% FCS-DMEM. For mineralization assays, cells were cultured in 10%
FCS-DMEM until confluent (day 0), and then in 10% FCS-DMEM and 3
or 5 mM b-glycerophosphate (b-GP) for up to 18 days.19 Controls were
cultured without b-GP. Four preparations of uncloned VSMCs isolated
from different animals were used for these studies; different batches of
cells were used in independent experiments. Unless otherwise stated,
in vitro studies used bovine VSMCs. Cells were used between passage
10–13.
Human coronary artery VSMCs were routinely cultured in medium
231 supplemented with smooth muscle growth supplement (Gibco, Life
Technologies, UK). For mineralization assays, cells were cultured in
medium 231 supplemented with smooth muscle growth supplement
until confluent (day 0), and then with 5 mM b-GP and 0.9 mM calcium
chloride for up to 40 days. The final concentration of calcium chloride in
the human VSMC calcifying media was 2.5 mM. Controls were cultured
without b-GP and additional calcium chloride. Two preparations of
human VSMCs (passage 6–7) were used for these studies; different
batches of cells were used in independent experiments.
2.4 Small interfering RNAs (siRNAs)
VSMCs were transfected with siRNAs against syndecan-4 (S459980,
AmbionVR , Life Technologies, UK) or PKCa (SI01965138, Qiagen, UK)
using RNAiMAX (InvitrogenTM, Life Technologies, UK). A random con-
trol siRNA (#1027281; Qiagen, UK) was the control. All siRNAs were
used at a final concentration of 20 nM. For signalling assays, VSMCs were
cultured for up to 7 days, with repeated siRNA transfections every
48–72 h. For mineralization assays, VSMCs were transfected twice with
siRNA (with 48–72 h between transfections) prior to b-GP treatment.
During b-GP treatment, siRNAs were removed after 4 h and fresh
medium containing b-GP was added to the cells between transfections.
2.5 Alizarin red staining
Mineral deposition was confirmed by staining with 40 mM alizarin red
(pH 4.1) and quantified by dye elution.19 The absorbance values for
VSMC mineralization were: early mineralization (0.09–0.2), mid minerali-
zation (0.21–0.6), and late mineralization (>_0.61).
1640 S.J. Borland et al.
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2.6 Immunoblotting
Cell lysates were analysed for FGF-2, syndecan-4, phosphorylated
Smad2, Smad2, phosphorylated PKCa, PKCa, phosphorylated Akt, Akt,
phosphorylated Erk1/2, and Erk1/2 by immunoblotting.20 b-actin was the
loading control. Immunoblots were quantified using ImageJ.
2.7 RNA isolation and quantitative
polymerase chain reaction (qPCR)
RNA was isolated using the RNeasy Mini Kit (Qiagen) and cDNA synthe-
sized using TaqmanVR Reverse Transcription Reagents (InvitrogenTM, Life
Technologies). qPCR was performed using SYBR Green PCR master mix
(Applied Biosystems, Life Technologies) and the CFX96 or CFX384 Real-
Time PCR system (Bio-Rad, UK). Primer sequences are provided in the
Supplementary material online. All samples were amplified in duplicate
and averaged to produce one data-point. The expression of each gene
was normalized to the reference genes [ribosomal protein L12 (RPL12)
and peptidylprolyl isomerase A (PPIA)] using the comparative Ct method.
2.8 Statistical analysis
Data are presented as the mean ± standard error of the mean (SEM).
Data were normalized where required using log10 and statistical compar-
isons were made using t-tests or one-way ANOVA. Data with two or
more variables were analysed with a 2-way ANOVA. Where normality
could not be confirmed, data were analysed using a Mann-Whitney t-
test. A value of P< 0.05 was considered statistically significant.
3. Results
3.1 FGF-2 inhibits mineral deposition by
VSMCs
FGF-2 plays an instructive role in osteogenesis,12–14 but the potential
involvement of FGF-2 in vascular calcification was unknown. Therefore,
to investigate FGF-2 expression during VSMC mineralization, a well-
established in vitro model of vascular calcification was used.19 VSMCs
deposited a mineralized matrix when cultured from confluence (day 0)
in the presence of b-GP, and the extent of mineralization increased with
time (Figure 1A). No mineralization was detected in controls cultured
without b-GP (Figure 1A).
RNA and protein were isolated from VSMCs at specific time-points:
early mineralization (days 9–10), mid mineralization (days 10–12), and
late mineralization (days 12–18). RNA and protein were also isolated
from VSMCs cultured without b-GP at these same time-points. FGF-2
mRNA (40-fold increase; Figure 1B) and protein (2.5-fold increase;
Figure 1C) expression were significantly increased in b-GP-treated
VSMCs at late mineralization when compared to controls at the same
time-point. In contrast, FGF-2 expression was not increased in VSMC
preparations that do not deposit a mineralized matrix in the presence of
b-GP (Figure 1D) confirming that the changes observed in FGF-2 are
either necessary for, or are a consequence of, VSMC mineralization and
are not due to extended culture in the presence of b-GP.
To determine whether FGF-2 regulates VSMC mineralization, VSMCs
were cultured with b-GP plus vehicle or FGF-2 (25 or 50 ng/mL).
Exogenous FGF-2 significantly reduced b-GP-induced mineralization when
compared to the vehicle and b-GP control (Figure 2A). The addition of
FGF-2 at different time-points during the mineralization protocol (i.e. 0, 2,
4 or 6 days after addition of b-GP) also significantly reduced b-GP-induced
mineralization in VSMCs compared to controls (see Supplementary mate
rial online, Figure S1), suggesting FGF-2 can also suppress matrix mineraliza-
tion when added to cells which are primed to mineralize.
We next investigated the role of FGF-2-dependent fibroblast growth
factor receptor (FGFR) signalling during VSMC mineralization using the
pan-FGFR inhibitor BGJ398. BGJ398 markedly inhibited FGF-2-induced Akt
and Erk1/2 phosphorylation in VSMCs (Figure 2B); BGJ398 also increased
b-GP-induced VSMC mineralization compared to the vehicle and b-GP
control (4.5-fold increase with 1lM BGJ398; Figure 2C). This result was
verified in mineralizing human VSMCs (Figure 2D). BGJ398 did not induce
VSMC mineralization in the absence of raised phosphate levels (see
Supplementary material online, Figure S2A), nor did it induce mineralization
in preparations of VSMCs that do not mineralize in the presence of b-GP
(see Supplementary material online, Figure S2B), suggesting that inhibition of
FGFR signalling does not drive VSMC mineralization on its own, but it
accelerates mineralization in VSMCs that are already primed to mineralize.
3.2 FGF/TGFb cross-talk regulates mineral
deposition by VSMCs
The above results demonstrate FGF-2 and FGFR signalling reduce matrix
mineralization in VSMCs, but how FGF-2 mediates this effect was
unknown. Recent studies have shown that inhibiting FGF signalling
increases TGFb signalling in VSMCs.21,22 As TGFb1 accelerates mineral
deposition by calcifying vascular cells,23 we next investigated the rela-
tionship between FGF and TGFb signalling in VSMC mineralization.
To confirm TGFb signalling regulates VSMC mineralization, VSMCs
were cultured with b-GP plus vehicle or TGFb1 (0.1 or 1 ng/mL).
Exogenous TGFb1 significantly increased b-GP-induced VSMC minerali-
zation when compared to the vehicle and b-GP control (Figure 3A). In
contrast, inhibiting endogenous TGFb signalling using the type 1 TGFb
receptor (TGFbR1) kinase inhibitor, SB431542 (0.1 or 1mM), signifi-
cantly reduced VSMC mineralization when compared to the vehicle and
b-GP control (Figure 3B).
TGFbR activation leads to Smad2 phosphorylation.21,22 Previous studies
have shown that decreased Smad2 phosphorylation co-localizes with
increased FGFR1 phosphorylation in the medial layer of atherosclerotic
human coronary arteries.22 In the late stages of matrix mineralization,
Smad2 phosphorylation was significantly reduced in b-GP-treated VSMCs
when compared to controls at the same time-point (four-fold decrease;
Figure 3C). This decrease in Smad2 phosphorylation coincided with
increased FGF-2 expression in b-GP-treated VSMCs (compare Figures 1B,
1C and 3C).
To confirm FGF regulates TGFb signalling in VSMCs, FGFR signalling
was inhibited using BGJ398 and cells were incubated with TGFb1 for up
to 60 min. TGFb1-induced Smad2 phosphorylation was significantly
increased in VSMCs treated with BGJ398 after 30 and 60 min (Figure 3D);
this increase was prevented by co-incubation with SB431542 (Figure 3D).
The relationship between FGF and TGFb signalling in matrix mineraliza-
tion was also studied by incubating VSMCs with both inhibitors. As
before, BGJ398 significantly increased b-GP-induced VSMC mineraliza-
tion compared to the vehicle and b-GP control (Figure 3E); this increase
was prevented by co-incubation with SB431542 (Figure 3E). Together
these results suggest FGFR inhibition increases matrix mineralization by
up-regulating TGFb signalling in VSMCs.
3.3 Syndecan-4 expression co-localizes with
FGF-2 in calcified vessels
Syndecan-4 is a transmembrane HSPG that functions as an adhesion
receptor and growth factor co-receptor, eliciting signals in response to
FGF-2/syndecan-4 signaling and calcification 1641
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..the extracellular microenvironment.24,25 Atherosclerotic plaque sus-
ceptibility is increased in syndecan-4/low-density lipoprotein receptor
double knock-out mice fed a high-fat diet26; but its role in vascular calcifi-
cation was unknown. As syndecan-4 is a critical regulator of FGF-2 signal-
ling,27,28 we next investigated the potential involvement of syndecan-4 in
VSMC mineralization, and examined whether syndecan-4 regulates FGF-
2/TGFb signalling in this process.
Syndecan-4 mRNA expression was markedly increased in b-GP-
treated VSMCs, with a five-fold increase at late mineralization com-
pared to the same time-point controls (Figure 4A). This increase in
syndecan-4 mRNA expression coincided with increased FGF-2
expression and decreased Smad2 phosphorylation in b-GP-treated
VSMCs (compare Figures 1B, 1C, 3C and 4A). In contrast, syndecan-1
expression was significantly decreased in b-GP-treated VSMCs
compared to controls, with a two-fold decrease at late mineraliza-
tion (Figure 4A). No significant changes were detected in syndecan-2
or syndecan-3 mRNA expression (Figure 4A). Furthermore,
syndecan-1 and syndecan-4 mRNA expression did not change when
VSMC preparations which do not deposit a mineralized matrix in the
presence of b-GP were analysed (Figure 4B).
Syndecan-4 and FGF-2 expression in human atherosclerotic arteries
was also examined. FGF-2 and syndecan-4 staining was localized to areas
directly adjacent to, and within, calcified regions of atherosclerotic
arteries (representative images of three atherosclerotic lesions from
two different donors are shown in Figure 4Ci–iii). No staining was
observed in the rabbit IgG controls (Figure 4Ci–iii).
A
B
D
C
Figure 1 FGF-2 expression is up-regulated during VSMC mineralization. VSMCs (day 0) were incubated ± 3 mM b-GP for up to 18 days. (A) VSMCs were
stained with alizarin red (bar = 500mm) and mineral deposition quantified by dye elution (n= 6 independent experiments). FGF-2 expression was measured
using (B) qPCR (data expressed relative to day 0; n= 9 independent experiments) and (C) immunoblotting of cell lysates (FGF-2 is expressed relative to b-
actin; n= 6 independent experiments). Molecular weight markers are shown. (D) Two different preparations of non-mineralizing VSMCs were
cultured ± 5 mM b-GP from confluence (day 0) for up to 14 days. RNA was collected from cells at day 0, 9, 11, and 14. These time-points were chosen as
they correspond to the time for mineralizing VSMCs (1A) to reach early, mid or late mineralization. FGF-2 mRNA expression was measured using qPCR
(data expressed relative to day 0; n= 6 independent experiments). (A, D) Data are means ± SEM. (A, B, D) Data were normalized using log10 and analysed
using 2-way ANOVA with Sidak post-hoc tests. (C) Data were analysed using a Mann-Whitney t-test. *P< 0.05.
1642 S.J. Borland et al.
AB
C
D
Figure 2 FGF-2/FGFR signalling regulates VSMC mineralization. (A) VSMCs were cultured with vehicle ± 3 mM b-GP, or FGF-2 (25 or 50 ng/mL) and
3 mM b-GP, stained with alizarin red (bar = 500mm) and mineral deposition quantified (Vehicle, n= 4 independent experiments; Vehicle and b-GP, 25 ng/mL
FGF-2 and b-GP, 50 ng/mL FGF-2 and b-GP, n= 5 independent experiments). (B) VSMCs were serum-starved for 2 h with vehicle (‘veh’) or BGJ398 (0.01–
1mM), and stimulated with FGF-2 for 5 min. Vehicle-treated VSMCs not stimulated with FGF-2 were controls. Cell lysates were immunoblotted for phos-
phorylated Akt (pAkt), total Akt, phosphorylated Erk1/2 (pErk1/2), and total Erk1/2. Two independent experiments were performed with two different
concentrations of FGF-2 (25 and 50 ng/mL) with identical results; a representative immunoblot (50 ng/mL FGF-2) is shown. Molecular weight markers are
shown. (C) VSMCs were cultured with vehicle ± 3 mM b-GP, or BGJ398 (0.1 or 1lM) and 3 mM b-GP for up to 11 days, stained with alizarin red
(bar = 500mm) and mineral deposition quantified (n= 4 independent experiments). (D) Human VSMCs were cultured with vehicle ± 5 mM b-GP and
0.9 mM calcium chloride, or 1lM BGJ398 ± 5 mM b-GP and 0.9 mM calcium chloride, stained with alizarin red (bar = 500mm) and mineral deposition quanti-
fied (n= 7 independent experiments). (A, C, D) Data are means ± SEM. Data were normalized using log10 and analysed using a one-way ANOVA with
Dunnett post-hoc tests. *P< 0.05.
FGF-2/syndecan-4 signaling and calcification 1643
AB
C
D
E
Figure 3 FGFR/TGFb cross-talk regulates mineral deposition by VSMCs. (A) VSMCs were cultured with vehicle ± 3 mM b-GP, or TGFb1 (0.1 or 1 ng/mL)
and 3 mM b-GP, stained with alizarin red (bar = 500mm) and mineral deposition quantified (n= 3 independent experiments). (B) VSMCs were cultured with
1644 S.J. Borland et al.
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3.4 FGF-2 inhibits mineral deposition via
syndecan-4
To determine the role of syndecan-4 in VSMC mineralization, siRNA
was used to knock-down syndecan-4 expression (Figure 5A). Syndecan-4
knock-down significantly increased b-GP-induced VSMC mineralization
compared to control siRNA-treated cells cultured with b-GP (Figure
5B). Knocking-down syndecan-4 expression in VSMCs cultured in con-
trol media did not induce matrix mineralization on its own (see
Supplementary material online, Figure S3A). Furthermore, knocking-
down syndecan-4 expression in a preparation of VSMCs that do not
mineralize in the presence of b-GP did not induce matrix mineralization
(see Supplementary material online, Figure S3B).
Syndecan-4 knock-down or biochemical inhibition of FGF-2-
dependent FGFR signalling increases VSMC mineralization, suggesting
syndecan-4 and FGF-2 expression are increased in mineralizing VSMCs
to prevent further calcification. To investigate the link between FGF-2
and syndecan-4 in regulating VSMC mineralization, control siRNA-, and
syndecan-4 siRNA-transfected VSMCs were cultured with vehicle or
FGF-2 in the presence of b-GP. As before, FGF-2 inhibited mineralization
whereas syndecan-4 knock-down markedly increased mineralization
(Figure 5C). Furthermore, the inhibitory effect of FGF-2 on matrix miner-
alization was partially prevented by knocking-down syndecan-4 expres-
sion (Figure 5C). However, FGF-2 was still able to inhibit mineralization in
syndecan-4 knock-down VSMCs (Figure 5C), suggesting FGF-2 can also
signal independently of its co-receptor, syndecan-4.
Inhibiting FGFR signalling increases TGFb signalling in VSMCs (Figure
3D) and inhibiting TGFb signalling prevents FGFR inhibition from increas-
ing VSMC mineralization (Figure 3E). Therefore, to determine if TGFb
signalling is also responsible for the increased matrix mineralization in
syndecan-4 knock-down VSMCs, syndecan-4 siRNA-transfected VSMCs
were cultured with b-GP and vehicle or SB431542 (1lM). Control
siRNA-transfected VSMCs cultured with b-GP were used as controls.
Knocking-down syndecan-4 expression in VSMCs significantly increased
b-GP-induced matrix mineralization; this increase was prevented by co-
incubation with SB431542 (Figure 5D). These results suggest syndecan-4
and FGF-2 both suppress matrix mineralization by down-regulating
TGFb signalling in VSMCs.
3.5 PKCa signalling regulates mineral
deposition
The cytoplasmic domain of syndecan-4 interacts with, and activates,
PKCa29,30 and the syndecan-4/PKCa complex regulates FGF-2-induced
Akt phosphorylation in endothelial cells.27,28 To investigate the link
between FGF-2, syndecan-4 and PKCa in VSMCs, syndecan-4 and PKCa
were knocked-down using siRNA and the cells were incubated with
vehicle or FGF-2 for 5 min and down-stream signalling via Akt assessed.
FGF-2-induced Akt phosphorylation was reduced in syndecan-4 siRNA-
transfected VSMCs (Figure 6A) and PKCa siRNA-transfected VSMCs
(Figure 6B and C). Western blotting also revealed a trend towards
decreased phosphorylated PKCa during the late stages of VSMC miner-
alization (Figure 7A). Therefore, we next investigated whether PKCa reg-
ulates FGF-2/TGFb signalling and mineralization in VSMCs.
Knocking-down PKCa with siRNA (Figure 7B) or inhibiting PKCa
activity with Go¨6976 (1lM) (Figure 7C) significantly increased b-GP-
induced VSMC mineralization compared to the relevant controls.
Go¨6976 also increased mineralization in human VSMCs (Figure 7D).
Knocking-down PKCa expression in VSMCs cultured in control media
(see Supplementary material online, Figure S3A), or culturing VSMCs in
control media with Go¨6976 (see Supplementary material online, Figure
S3C) did not induce matrix mineralization. Also Go¨6976 did not induce
mineralization in a preparation of VSMCs that do not mineralize in the
presence of b-GP (see Supplementary material online, Figure S3D).
These results suggest that loss or inhibition of PKCa is not a driver of
VSMC mineralization per se, but it accelerates mineralization in VSMCs
which are already primed to mineralize.
To further define the link between FGF-2/syndecan-4 and PKCa in
regulating VSMC mineralization, control siRNA- and PKCa siRNA-
transfected VSMC were cultured with vehicle or FGF-2 in the presence
of b-GP. As before, FGF-2 reduced mineralization whereas PKCa
knock-down markedly increased mineralization (Figure 7E). PKCa
knock-down reduced the inhibitory effect of FGF-2 on mineralization
(Figure 7E), suggesting the FGF-2/syndecan-4 signalling axis may, at least
in part, regulate VSMC mineralization via PKCa. FGF-2 was still able to
inhibit mineralization in PKCa knock-down VSMCs (Figure 7E), suggest-
ing that FGF-2 can also signal via other downstream signalling pathways.
To determine if increased TGFb signalling mediates the increased min-
eralization in PKCa knock-down VSMCs, PKCa siRNA-transfected
VSMCs were cultured with b-GP and vehicle or SB431542 (1lM).
Control siRNA-transfected VSMCs cultured with b-GP were controls.
SB431542 prevented PKCa knock-down from increasing b-GP-induced
matrix mineralization in VSMCs (Figure 7F), suggesting loss of PKCa
increases matrix mineralization by up-regulating TGFb signalling in
VSMCs.
4. Discussion
We demonstrate the expression of FGF-2 and its co-receptor, synde-
can-4, are increased in mineralizing VSMCs and at sites of calcification in
vehicle ± 3 mM b-GP, or SB431542 (0.1 or 1lM) and 3 mM b-GP, stained with alizarin red (bar = 500mm) and mineral deposition quantified (n= 3 inde-
pendent experiments). (C) VSMCs were incubated ± 3 mM b-GP for up to 18 days. Cell lysates were isolated at late VSMC mineralization and immunoblot-
ted for phosphorylated Smad2 (pSmad2), total Smad2, and b-actin on the same membrane. Molecular weight markers are shown. The pSmad2/Smad2 ratio
is expressed relative to b-actin (n= 6 independent experiments). (D) VSMCs were serum-starved for 2 h (‘0’) with vehicle, BGJ398 (1mM), or with BGJ398
(1mM) and SB431542 (1mM), stimulated with 0.5 ng/mL TGFb1 for 15, 30 or 60 min and immunoblotted for phosphorylated Smad2 (pSmad2), total Smad2,
and b-actin on the same membrane. Molecular weight markers are shown. The pSmad2/Smad2 ratio is expressed relative to b-actin (vehicle, BGJ398, n= 6
independent experiments; BGJ398 with SB431542, n¼ 3 independent experiments). (E) VSMCs were cultured with vehicle ± 5 mM b-GP, 5 mM b-GP and
BGJ398 (1mM), or with 5 mM b-GP, BGJ398 (1mM) and SB431542 (1mM), stained with alizarin red (bar = 500mm) and mineral deposition quantified (n= 4
independent experiments). (A–E) Data are means ± SEM. (A, B, E) Data were normalized using log10 and analysed using a one-way ANOVA with Dunnett
post-hoc tests. (C) Data were analysed using a Mann-Whitney t-test. (D) Data were analysed using a 2-way ANOVA with Sidak post-hoc tests. *P< 0.05.
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A B
Figure 4 Syndecan-4 expression co-localizes with FGF-2 in vascular calcification. (A) VSMCs (day 0) were incubated ± 3 mM b-GP for up to 14 days. The
mRNA levels of syndecan-1-4 were measured using qPCR (as in Figure 1B; n= 9 independent experiments for syndecan-1 and syndecan-4; n= 6 independent
experiments for syndecan-2 and syndecan-3). (B) Two different preparations of non-mineralizing VSMCs were cultured ± 5 mM b-GP from confluence (day
0) for up to 14 days and the expression levels of syndecan-1 and syndecan-4 were measured using qPCR (as in Figure 1D; n= 6 independent experiments).
(A, B) Data are means ± SEM. Data were normalized using log10 and analysed using 2-way ANOVA with Sidak post-hoc tests. *P< 0.05. (C) Atherosclerotic
coronary artery specimens stained with von Kossa’s reagent for calcification (black), anti-FGF-2 antibody, anti-syndecan-4 antibody, or rabbit IgG. FGF-2 and
syndecan-4 (brown) localize to areas adjacent to, or within, calcified regions in atherosclerotic plaques ((Ci), plaque with extensive calcification, patient 167;
(Cii), plaque with more diffuse calcification, patient 167; (Ciii) plaque with spicules of calcification, patient 161). (Ci-iii) Rabbit IgG controls are negative.
Bars = 200mm.
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Figure 5 Knocking-down syndecan-4 rescues the inhibitory effect of FGF-2 on VSMC mineralization. (A) Syndecan-4 expression was knocked-down in
VSMCs using siRNA and confirmed using qPCR (upper panel) and immunoblotting (lower panel) (n= 4 independent experiments). (B) VSMCs transfected
with syndecan-4 siRNA were cultured with 3 mM b-GP for up to 9 days. Control siRNA-treated VSMCs cultured ± 3 mM b-GP were controls. Cells were
stained with alizarin red (bar = 500mm) and mineral deposition quantified (n= 8 independent experiments). Results were verified using a different siRNA oli-
gonucleotide sequence to target syndecan-4 in VSMCs (not shown). (C) Control siRNA and syndecan-4 siRNA-treated VSMCs were cultured with 5 mM b-
GP and vehicle or FGF-2, stained with alizarin red (bar = 500mm) and mineral deposition quantified (Control siRNA/b-GP, Control siRNA/b-GP/FGF-2 and
Syndecan-4 siRNA/b-GP/FGF-2, n= 6 independent experiments; Syndecan-4 siRNA/b-GP, n= 4 independent experiments). (D) Syndecan-4 siRNA-treated
VSMCs were cultured with 5 mM b-GP and vehicle or SB431542 (1mM). Control siRNA-treated VSMCs cultured with 5 mM b-GP and vehicle were con-
trols. Cells were stained with alizarin red (bar = 500mm) and mineral deposition quantified (n= 4 independent experiments). (A–D) Data are means ± SEM.
(A) Data were normalized using log10 and analysed using a t-test. (B, D) Data were normalized using log10 and analysed using a one-way ANOVA with
Dunnett post-hoc tests. (C) Data were normalized using log10 and analysed using a one-way ANOVA with Tukey post-hoc tests. *P< 0.05.
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.human atherosclerotic plaques, and that biochemical inhibition of FGFR
signalling or knocking-down syndecan-4 expression increases VSMC
mineralization. Importantly, syndecan-4 is, at least in part, responsible for
the inhibition of VSMC mineralization by FGF-2, suggesting syndecan-4
expression is increased in mineralizing VSMCs to maintain FGF-2 signal-
ling. We also show syndecan-4 and FGF-2 signalling suppress the deposi-
tion of a mineralized matrix by down-regulating TGFb signalling. Finally,
we demonstrate that PKCa, which is activated in a cytoplasmic domain-
dependent manner by syndecan-4,29,30 regulates FGF-2/TGFb signalling
and mineralization in VSMCs. Together, these results demonstrate a
novel feedback mechanism whereby mineralizing VSMCs increase FGF-2
and syndecan-4 expression and down-regulate TGFb signalling to pre-
vent more extensive calcification (Figure 8).
This is the first demonstration that FGF-2 expression is increased in
mineralizing VSMCs in vitro, and that FGF-2 is localized to calcified
regions of human atherosclerotic plaques. Consistent with these findings,
FGF-2 is expressed adjacent to calcified regions in valve leaflets.31 FGF-2
mRNA expression is also increased during the osteogenic differentiation
A
B C
Figure 6 Syndecan-4 and PKCa regulate FGF-2/Akt signalling in VSMCs. (A) Control and syndecan-4 siRNA-treated VSMCs were serum-starved for 2 h
(0) and stimulated with vehicle or FGF-2 (25 and 50 ng/mL) for 5 min. Cell lysates were immunoblotted for phosphorylated Akt (pAkt) and total Akt; b-actin
was the loading control (n= 6 independent experiments). Molecular weight markers and the pAkt/Akt ratio are shown. (B) PKCa expression was knocked-
down in VSMCs using siRNA and confirmed using qPCR (upper panel) and immunoblotting (lower panel) (n= 4 independent experiments). (C) FGF-2/Akt
signalling assays were performed with control and PKCa siRNA-treated VSMCs as described in (A) (n= 5 independent experiments). Molecular weight
markers and the pAkt/Akt ratio are shown. (A–C) Data are means ± SEM. (A, C) Data were analysed using a 2-way ANOVA with Sidak post-hoc tests. (B)
Data were normalized using log10 and analysed using a t-test. *P< 0.05.
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Figure 7 Inhibiting PKCa activity with Go¨6976, or knocking-down PKCa expression using siRNA, increases VSMC mineralization. (A) VSMCs (day 0)
were incubated ± 3 mM b-GP for up to 14 days. Cell lysates were isolated at late VSMC mineralization and immunoblotted for PKCa phosphorylation
(pPKCa), total PKCa, and b-actin on the same membrane (n= 3 independent experiments). Molecular weight markers and the pPKCa/PKCa ratio are
shown. (B) VSMCs transfected with control siRNA or PKCa siRNA were cultured with 3 mM b-GP for up to 9 days, stained with alizarin red (bar = 500mm)
and mineral deposition quantified (n= 6 independent experiments). (C) VSMCs were cultured with 3 mM b-GP and vehicle or 1lM Go¨6976 for up to
11 days, stained with alizarin red (bar = 500mm) and mineral deposition quantified (n= 3 independent experiments). (D) Human VSMCs were cultured with
vehicle ± 5 mM b-GP and 0.9 mM calcium chloride, or 1lM Go¨6976 ± 5 mM b-GP and 0.9 mM calcium chloride, stained with alizarin red (bar = 500mm) and
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..and mineralization of osteoprogenitors,32 and is expressed at sites of
bone formation in vivo.33 FGF-2 plays a complex role in osteoblast miner-
alization, with its effects dependent on the timing and duration of signal-
ling.12–14 Consistent with these studies, we show that continuous FGF-2
treatment inhibits b-GP-induced VSMC mineralization. The addition of
FGF-2 after the commencement of b-GP treatment also reduces VSMC
mineralization, supporting the suggestion that increases in FGF-2 expres-
sion during late mineralization may put a ‘brake’ on this process. Indeed,
FGF-2 stimulates the osteogenic potential of calvarial osteoblasts and
mesenchymal stem cells during the early stages of differentiation, but
must then be down-regulated for mineralization to proceed.12–14
It is well established that syndecan-4 is a critical regulator of FGF-2 sig-
nalling,27,28 but it is currently unknown how the transcription of
syndecan-4 and FGF-2 is regulated in mineralizing VSMCs. Previous stud-
ies have reported that FGF-2 synergizes with Runx2 to enhance
syndecan-4 mRNA expression in calvarial osteoblasts,34 but we found
that 24-h FGF-2 treatment has no effect on syndecan-4 mRNA expres-
sion in VSMCs (see Supplementary material online, Figure S4). It is possi-
ble, therefore, that raised levels of Runx2 are required for FGF-2 to
induce syndecan-4 expression in these cells e.g. as observed during
VSMC osteogenic differentiation and mineralization.
A role for TGFb1 in vascular calcification was first suggested by
Watson et al. who reported TGFb1 increased mineralized nodule forma-
tion in bovine calcifying vascular cells.23 More recent studies have shown
that inhibition of TGFbR1 using SB431542 inhibits VSMC
mineralization.35,36 We also show that TGFb1 accelerates mineral depo-
sition by bovine VSMCs, whereas SB431542 inhibits it. Furthermore, we
show FGF-2 expression is increased in mineralizing VSMCs and TGFb
signalling is concomitantly reduced to minimize further calcification.
Previous studies in VSMCs have shown that suppressing FGF signalling
results in reduced let-7 microRNA, leading to increased TGFbR1 recep-
tor expression and TGFb signalling activation.22 It is therefore possible
that FGF-2/TGFb cross-talk may also be mediated via let-7 microRNA in
mineralizing VSMCs.
Several studies have suggested PKCa normally acts to suppress bone
formation.37,38 Consistent with a previous study in mouse VSMCs,39 we
show that inhibiting PKCa activity with Go¨6976 or knocking-down
PKCa expression increases VSMC mineralization. Moreover, we dem-
onstrate that this increase in mineralization is prevented by inhibiting
TGFbR1 signalling. The crucial role of PKCa in regulating mineralization
is further highlighted by our demonstration that knocking-down PKCa
reduces the ability of FGF-2 to inhibit VSMC mineralization. Over-
expressing PKCa in an osteoblastic cell line reduces alkaline phosphatase
activity and the expression of osteogenic marker genes in these cells37;
however, the effects of over-expressing PKCa on osteoblast or VSMC
mineralization are unknown. As PKCa is downstream of FGF-2/
syndecan-4, a possible focus for therapeutic targeting in vascular calcifica-
tion may be the modulation of PKCa activation/signalling in VSMCs.
A potential limitation of our study is that the signalling data were
obtained following short-term incubation of the VSMCs with growth
Figure 8 Schematic diagram demonstrating how cross-talk between syndecan-4, FGF-2, and TGFb signalling may regulate calcification. Not to scale.
mineral deposition quantified (n= 7 independent experiments). (E) Control siRNA and PKCa siRNA-treated VSMCs were cultured with 5 mM b-GP and
vehicle or FGF-2, stained with alizarin (bar = 500mm) and mineral deposition quantified (Control siRNA/b-GP, Control siRNA/b-GP/FGF-2, and PKCa
siRNA/b-GP/FGF-2, n= 6 independent experiments; PKCa siRNA/b-GP, n= 3 independent experiments). (F) PKCa siRNA-treated VSMCs were cultured
with 5 mM b-GP and vehicle or SB431542 (1mM). Control siRNA-treated VSMCs cultured with 5 mM b-GP and vehicle were used as controls. Cells were
stained with alizarin red (bar = 500mm) and mineral deposition quantified (n= 3 independent experiments). (A–F) Data are means ± SEM. (B, C) Data were
normalized using log10 and analysed using a t-test. (D, F) Data were normalized using log10 and analysed using a one-way ANOVA with Dunnett post-hoc
tests. (E) Data were normalized using log10 and analysed using a one-way ANOVA with Tukey post-hoc tests. *P< 0.05.
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factors and/or inhibitors; whereas the mineralization data were obtained
following incubation of the cells with these same reagents for up to
14 days. However, although caution should be taken when extrapolating
between these two sets of data, our study clearly demonstrates that sig-
nalling and mineralization are both affected by these treatments.
Whilst our results indicate an important role for syndecan-4 in regu-
lating FGF-2/TGFb signalling during VSMC mineralization, other PGs
could also regulate these signalling pathways in this process. Indeed, our
data show the expression levels of several other PGs are modulated dur-
ing VSMC mineralization (see Supplementary material online, Figure S5).
For example, glypican-4 expression is also up-regulated in b-GP-treated
VSMCs (see Supplementary material online, Figure S5). Glypican-4 binds
FGF-240 and may therefore also affect FGF-2/FGFR signalling in VSMCs,
although glypican-4 wouldn’t directly activate PKCa. Decorin has also
been shown to promote mineralization by increasing TGFb signalling in
VSMCs.35 Future studies could, therefore, determine whether these PGs
also regulate FGF-2 and TGFb cross-talk during VSMC mineralization.
In conclusion, our study has identified a novel potential therapeutic
target pathway in the control of vascular disease. We highlight syndecan-
4/FGF-2/TGFb signalling as a critical regulator of VSMC mineralization.
Intriguingly, both syndecan-4 and FGFR signalling appear to be important
in this process. It remains to be determined whether syndecan-4 and
FGFR regulate mineralization in convergent or parallel pathways. It is
possible that syndecan-4 may act to prevent excessive mineralization via
two mechanisms: (a) interacting as a co-receptor for FGF-2 and inducing
down-stream signalling via FGFR and (b) via interaction with PKCa.
These pathways may then coalesce to suppress mineralization induced
by TGFb. Although this dual activity of syndecan-4 is well established in
other systems (e.g. during neural induction41) its role here is of particular
importance given the current need for novel drugs to treat vascular
disease.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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